Palvella Therapeutics said its 3.9% topical rapamycin gel produced clinical improvements in a mid-stage trial for a rare pediatric skin disease, reporting positive Phase 2 data. The company highlighted symptomatic improvement and tolerability; detailed metrics and safety tables were cited in the company release. Topical rapamycin targets mTOR signalling and has been explored in dermatology for vascular and proliferative lesions. Palvella plans next steps toward registration-directed development pending further analysis.